Innostar succefully assisted Signet Therapeutics in the IND approval by U.S. FDA of the world's first targeted drug for the treatment of diffuse gastric cancer
In the morning of February 1st, "the first round signing and groundbreaking ceremony of major science & technology industrial and supporting projects in 2023" was held in Pudong New Area with the theme of "Taking the Lead, Fighting for Speed and Breaking New Ground".
Shenzhen InnoStar Biomedical Safety Evaluation and Research Institute Co., Ltd. has successfully received the good laboratory practice (GLP) certification for conducting non-clinical studies from the National Medical Products Administration and become the first GLP-certified CRO company in Shenzhen.
Address: 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, China
Postcode: 201203
Tel: +86-21-60211999
services@innostarbio.com
86-021-xxxxxxx
Scan the QR code
Subscription to our Wechat account
Copyright © 2017-2021©Shanghai InnoStar Bio-tech Co., Ltd. All Rights Reserved. Created By VPABrand.com
